Glioma

Indexed in Crossref

37 abstracts matching glioma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 11:27 UTC. This is a keyword search, not the complete abstract book.

• E14082
  Pilocytic astrocytoma: An NCDB analysis of contemporary clinical and socioeconomic patterns.

  Akaash Surendra, Grace Nguyen, Suraj Puvvadi, Beau Hsia et al.
• E14070
  Genomic profiling of diffuse intrinsic pontine glioma in AACR Project GENIE.

  Akaash Surendra, Savita Prasad, Amber Chang, Suraj Puvvadi et al.
• E14000
  AI–assisted survival prediction in glioma: Meta-analysis of prospective and controlled studies.

  Shradha P. Kakde, Meghnath P. Kakde, Niraj Arora, Shubhangi Pandurang Kakade
• E14102
  National inpatient outcomes and hospital-volume disparities after glioma resection: A HCUP NIS analysis.

  Sukhmani Sidhu, Harendra Kumar, Ashish Sharma, Angad Tiwari et al.
• 2074
  Phase II clinical study of ACT001 combined with radiotherapy in newly diagnosed pediatric diffuse intrinsic pontine glioma.

  Jing Zhang, Xiaoguang Qiu, Yanwei Liu
• E14057
  Real-world assessment of treatment adherence among vorasidenib-treated patients with IDH-mutant glioma.

  Qingqing Xu, Mallika P. Patel, Irene Nsiah, Rana Elkholi et al.
• E14059
  Phase II study of liposomal irinotecan in combination with cisplatin and bevacizumab for high-grade recurrent glioma.

  Weiyan Shi, Jianfeng Wang, Rui LIU, Ye Zhang et al.
• E14086
  An AI-integrated patient-derived organoid platform to enable high-throughput drug response prediction in glioma.

  Zhaoshi Bao, Zheng Fang, Chengjun Zheng, Baolin Shao et al.
• E14006
  Deep learning–derived MRI features for risk stratification in post-surgical IDH -mutant glioma.

  Alvaro Sandino, Marwa Ismail, Krithi Gopinath, Gustavo Pineda et al.
• E14054
  Geographic access to ONC201 (dordaviprone) trials for pediatric diffuse midline glioma in the United States: County travel burden and social vulnerability gradients.

  Jay Shah, Alaa Mahmoud, Khaled M. El-Husseiny
• E14077
  Genomic landscape and evolutionary dynamics of RAS alterations in glioma: A large-scale clinicopathologic analysis.

  Rosalina Magalhaes Pereira, Subhiksha Nandakumar, Anne S. Reiner, Tejus Bale et al.
• E14084
  Clinical and molecular predictors of postoperative seizure outcomes in adult low-grade glioma.

  Nidhi Vadhavekar, Garima Misra, Bisma Bashir Ahmed, Christian Cortes et al.
• 2053
  Genomic determinants of radiation necrosis in diffuse glioma patients.

  Michael Kienhöfer, Xiaohan Chi, Surya Bhat, Erick Campbell et al.
• TPS2100
  A trial to evaluate CSF ctDNA and safety of plixorafenib alone or with retifanlimab in patients with BRAF-altered glioma.

  Karisa C. Schreck, Peng Huang, Michaella Iacoboni, Alfredo Guastella et al.
• E14088
  PTPRZ1–MET fusion and induction of reprogrammed immuno-microenvironment via MET–IFN-β–LGALS9 signaling pathway during IDH-mutant glioma progression.

  Zhaoshi Bao, Chengjun Zheng, Qiaodong Chen, Zheng Fang et al.
• E14085
  Ultra-lightweight deep learning for glioma detection: MobileNet-based MRI classification to enable real-time neuro-oncology deployment.

  Mustafa Abrar Zaman, Elangovan Krishnan, Sophia Ahmed, Gowrishankar Palaniswamy et al.
• 2014
  Butaselen combined with radiotherapy for newly diagnosed H3K27M-mutant spinal diffuse midline glioma: A single-arm phase Ib trial.

  Yuanhao Chang, Hanwei Yin, Huihui Zeng, Yongzhi Wang et al.
• E14098
  Extent of resection and survival in IDH -mutant WHO grade 2 glioma: A systematic review and meta-analysis.

  Sukhmani Sidhu, Ashish Sharma, Harendra Kumar, Yara Hamadah et al.
• 2040
  Use of knowledge-distilled EfficientNet to enable rapid, scalable glioma diagnosis.

  Gowrishankar Palaniswamy, Elangovan Krishnan, Jansi Rani Sethuraj, Aravind Raghavan et al.
• 2057
  Which treatment is best? A systematic review and Bayesian network meta-analysis of adjuvant treatments for low-grade glioma.

  Amit Kumar Chowdhry, Mame Daro Faye, Huma Chaudhry, John Parel et al.
• E14076
  5–aminolevulinic acid fluorescence-guided surgery vs conventional white-light resection in glioma: A systematic review and meta-analysis.

  Muhammad Talha Khan, Sara Mohammed Darawish, Anas Barabrah, Muhammad Sohaib Khan et al.
• 2012
  First-in-human study of AAV6-NeuroD1 trans-differentiation therapy in recurrent malignant glioma.

  Yulun Huang, Gong Chen, HaiPing Zhu, Yu Zhang et al.
• 2083
  Knowledge distillation for glioma diagnosis: ResNet-based deep learning for WHO grade stratification with real-world deployment optimization.

  Sravani Bhavanam, Elangovan Krishnan, Jansi Rani Sethuraj, Kavin Elangovan et al.
• 2060
  Real-world outcomes from 3D-PREDICT glioma chemosensitivity testing of primary CNS tumors.

  Aidan Jones, Yazmin Odia, Lydia Hodgson, Matthew D. Hall et al.
• 2530
  Anti-tumor activity of Man 9 x PS targeting immunotherapies in diffuse intrinsic pontine glioma (DIPG) and pancreatic cancers.

  Shabnam Samimi, Jiadong Li, Kelly Mulraney, Derek Adler et al.
• E14073
  Radiotherapy combined with temozolomide and fluoxetine for newly diagnosed grade 4 glioma: Preliminary report from a single-arm, prospective phase II clinical trial.

  Zhigang Liu, Liji Jiang, Zhiqiang Wang, Zhijie Liu et al.
• TPS2103
  Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH -mutated newly diagnosed grade 3 astrocytoma (VORTEX).

  Ugonma Nnenna Chukwueke, Rifaquat Rahman, Susan Michelle Geyer, Rachael A. Vaubel et al.
• E14043
  Access-related disparities and survival in high-grade glioma: A social vulnerability analysis at a Texas tertiary cancer center.

  Aileen H. Hsi, Chetna Wathoo, Erick Campbell, Mohammed Nassif et al.
• E14081
  Blood-derived small extracellular vesicle-based liquid biopsy for repeatable genomic and transcriptomic monitoring in adult-type diffuse glioma.

  Gagan Deep, Ashish Kumar, Yangen He, Susy Kim et al.
• 2072
  Intrathecal iPSC-derived natural killer cells combined with the Stupp regimen for newly diagnosed WHO grade 4 glioma: A phase I trial.

  Yulun Huang, Xiang Li, Xuetao Li, Yang Zhang et al.
• 2058
  Characterization of contemporary practice patterns in the management of IDH -mutant glioma: A multidisciplinary multi-institutional survey.

  Luis Nicolas Gonzalez Castro, Tyler Ashford Lanman, Haley Kopp Perlow, Gilbert Youssef et al.
• 2067
  A 3D tumorwide multi-omic atlas of intratumoral heterogeneity in IDH -mutant glioma.

  Benjamin Joshua Lerman, Olivia Doyle, Ellen Chen, Lee Chen et al.
• E14060
  Tumor-agnostic and cross-indication actionable alterations in IDH -wildtype glioma: Precision oncology opportunities in an aggressive disease.

  Nitesh Rohatgi, Darshana Suresh Patil, Kunjahari Medhi, Priya Tiwari et al.
• 2080
  Tumor recurrence or treatment effect? Large multi-institutional evaluation of an AI risk assessment model in glioma and brain metastases.

  Dheerendranath Battalapalli, Hyemin Um, Sunil Manjila, Dantong Xiang et al.
• 2005
  Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: Final results from the phase 2a step (OLA-TMZ-RTE-01).

  Dinu Stefan, Justine Lequesne, Pierre Kubicek, Sunyach Marie et al.
• E14056
  Study of the cytostatic effect of a new compound of the tropolon series on primary cultures of glioma cells.

  Tatiana V. Chembarova, Nadezhda V. Gnennaya, Svetlana Yu Filippova, Irina V. Mezhevova et al.
• 2010
  A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): Updated efficacy and safety.

  Timothy Francis Cloughesy, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat et al.